Mar. 29 2010
Source Page: Reducing cancer inequality: evidence, progress and making it happen. 101 p.Found: Reducing cancer inequality: evidence, progress and making it happen. 101 p.
Jan. 14 2009
Source Page: Equal access to breast and cervical screening for disabled women. Cancer screening series no. 2. 48 p.Found: Equal access to breast and cervical screening for disabled women.
Asked by: Taiwo Owatemi (Labour - Coventry North West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps the Warwickshire, Solihull and Coventry Breast Screening Unit is taking as part of the breast screening improvement plan; what the timeline is for their delivery; and how much funding has been allocated for their delivery.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England Midlands is the responsible commissioner for the NHS Breast Cancer Screening Programme delivered across the Warwickshire, Solihull, and Coventry locality. The Warwickshire, Solihull, and Coventry service is one of the largest breast screening services in England, inviting approximately 55,000 people for screening each year.
NHS England Midlands has advised that for the breast screening improvement plan, work has begun on reviewing coverage for the Warwickshire, Solihull, and Coventry breast screening services. The service continues to collaborate with primary care practices to promote uptake for patients in low uptake areas, and staff facilitate local community events to educate on the importance of breast screening, for instance at the Godiva and Pride Festivals in Coventry.
In 2024/25 the service will receive a contract value in excess of £3 million, to ensure that cancer is detected early through screening. The service has also received capital investment during the last two years, which has supported additional imaging equipment to increase overall screening capacity within the service and pathway.
Work continues to ensure the current breast screening provision is improving, and once coverage has returned to pre-pandemic levels, NHS England Midlands hope to go further on ambitions to decrease inequity across all cancer screening programmes.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that patients at high risk of developing breast cancer are recalled for MRI screening.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Women at very high risk (VHR) of breast cancer are eligible to be screened from the age of 25 years old upwards, and should be invited every year. The screening includes mammography or magnetic resonance imaging (MRI), depending on age and risk criteria.
In March, NHS England wrote to a small number of VHR women who had not been referred for annual MRI surveillance, and the National Health Service has been working hard to ensure these women are checked as a matter of urgency, as described in their individual letters. To support screening of VHR women, a new central database is planned to ensure all referrals reach NHS breast screening services.
Nov. 01 2011
Source Page: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. [Published article.] 12 p.Found: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International
Dec. 09 2008
Source Page: Cancer Reform Strategy: maintaining momentum, building for the future - first annual report. 67 p.Found: Cancer Reform Strategy: maintaining momentum, building for the future - first annual report. 67 p.
Asked by: Peter Gibson (Conservative - Darlington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the adequacy of availability of follow up MRI scans for women who have undergone mastectomies to tackle lobular breast cancer.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
£2.3 billion was awarded at Spending Review 2021 to transform diagnostic services over the next three years. Most of this will help increase the number of community diagnostic centres up to 160 by March 2025, expanding and protecting elective planned diagnostic services. The remainder of the funding will increase capacity for imaging, including MRI scans, endoscopy as well as lung and mammography screening, and improve digital diagnostics.
Growth in the MRI asset base and increased use of MRI acceleration software is creating additional capacity for approximately 572,000 MRI examinations per annum within the NHS in England.
The Department and NHS England have taken steps to improve the treatment of invasive lobular breast cancer (ILBC) but are aware that more needs to be done. In September 2022, the National Cancer Audit Collaborating Centre announced funding from NHS England and the Welsh Government of £5.4 million to support delivery of six new national cancer audits. Two of these focus on breast cancer, one on primary and one on metastatic, and include ILBC.
Additionally, the National Institute for Health and Care Research (NIHR) supports breast cancer research funded by research partners in the charity and public sectors. Over the last five years, the NIHR Clinical Research Network has supported 10 ILBC-related studies.
Asked by: Ruth Cadbury (Labour - Brentford and Isleworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many applications for research grant funds for studies into lobular breast cancer have been submitted to the National Institute for Health and Care Research in the last 24 months.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department invests in health research through the National Institute for Health and Care Research (NIHR). NIHR invests in research, clinical expertise, specialist facilities, workforce and support services across a range of clinical areas. NIHR expenditure on cancer research was £121.8 million in 2022/23.
The Department and NIHR are aware of lobular breast cancer and issues in detection and treatment. Lobular breast cancers can be hard to detect through screening. Relevant research includes a £1.3 million NIHR research project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening mammography. We would urge researchers working on lobular breast cancer to submit research bids for NIHR funding, including applications to fund the United Kingdom arm of international studies. Details on eligibility and how to apply for Departmental research funding through the NIHR is available and updated on the NIHR website.
Since 2021/22, there have been five research grant bids for NIHR funding into lobular breast cancer. The above project was a successful research bid, while there were four unsuccessful applications judged by a scientific panel of peers during the same period. NIHR also supports research on lobular breast cancer through its research infrastructure including Biomedical Research Centres (BRCs). Researchers at NIHR Manchester BRC have shown that women at increased risk of breast cancer who were offered enhanced screening were more likely to survive in the long-term. In addition, NIHR supports breast cancer research funded by research partners in the charity and public sectors through the NIHR’s Clinical Research Network (CRN). Over the last five years the CRN has supported 10 lobular breast cancer-related studies.
The NIHR welcomes funding applications for research into any aspect of human health, including lobular breast cancer. The Department also continues to work closely with research funding partners such as Cancer Research UK and cancer charities, who fund research into new scientific discoveries.
Mar. 13 2024
Source Page: Letter dated 03/04/2024 from Steve Russell, National Director for Vaccination and Screening and Chief Delivery Officer, NHS England, and Deborah Tomalin, Director of Screening, NHS England to Victoria Atkins MP and Jonathan Marron, Director-General, Department of Health and Social Care, regarding referrals into the very high risk breast screening programme - action the NHS is taking to support affected women. 5p.Found: of Screening, NHS England to Victoria Atkins MP and Jonathan Marron, Director-General, Department of Health
Asked by: Virginia Crosbie (Conservative - Ynys Môn)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will provide £20 million of funding for research for the Lobular Moon Shot Project.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department invests in health research through the National Institute for Health and Care Research (NIHR). NIHR invests in research, clinical expertise, specialist facilities, workforce and support services across a range of clinical areas. NIHR expenditure on cancer research was £121.8 million in 2022/23.
The Department and NIHR are aware of lobular breast cancer and issues in detection and treatment. Lobular breast cancers can be hard to detect through screening. Relevant research includes a £1.3 million NIHR research project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening mammography. We would urge researchers working on lobular breast cancer to submit research bids for NIHR funding, including applications to fund the United Kingdom arm of international studies. Details on eligibility and how to apply for Departmental research funding through the NIHR is available and updated on the NIHR website.
Since 2021/22, there have been five research grant bids for NIHR funding into lobular breast cancer. The above project was a successful research bid, while there were four unsuccessful applications judged by a scientific panel of peers during the same period. NIHR also supports research on lobular breast cancer through its research infrastructure including Biomedical Research Centres (BRCs). Researchers at NIHR Manchester BRC have shown that women at increased risk of breast cancer who were offered enhanced screening were more likely to survive in the long-term. In addition, NIHR supports breast cancer research funded by research partners in the charity and public sectors through the NIHR’s Clinical Research Network (CRN). Over the last five years the CRN has supported 10 lobular breast cancer-related studies.
The NIHR welcomes funding applications for research into any aspect of human health, including lobular breast cancer. The Department also continues to work closely with research funding partners such as Cancer Research UK and cancer charities, who fund research into new scientific discoveries.